TNF Inhibitor Drugs Market Worth $42.1 Billion By 2026 | CAGR: 0.5%

The global tumor necrosis factor inhibitor drugs market size is anticipated to reach USD 42.1 billion by 2026, according to a report published by Grand View Research, Inc. Increasing prevalence of autoimmune diseases, rapid technological advancements, and rise in healthcare expenditure across the globe are some of the major factors expected to drive the growth.

Currently, there are five approved TNF inhibitor drugs in the market- Humira (adalimumab), Enbrel (etanercept), Remicade (infliximab), Simponi/Simponi Aria (golimumab), and Cimzia (certolizumab). Biosimilar versions of Humira, Enbrel, and Remicade have been launched, causing a significant paradigm shift in the market.

The wave of biosimilars pose a significant internal threat to the biologics sale as biosimilars have a comparable efficiency as the original products. The cost-effectiveness of biosimilars makes them an attractive choice in economically sensitive areas. In addition, emerging countries, such as India, China, and South Korea are active participants in the biosimilar market.

Some of the key therapeutic areas involving treatment with TNF inhibitor drugs are rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. Although these medicines are mostly used for the treatment of autoimmune diseases, several ongoing studies are investigating the role of TNF inhibitors in the treatment of cancer and other inflammatory conditions.

Some of the key players in the TNF inhibitor space are involved in strategic initiatives, such as mergers and acquisitions and joint ventures for the co-development of products. In addition, patent infringement issues between the manufacturers makes the market dynamics intensely competitive. For instance, AbbVie resolved an issue with Boehringer Ingelheim, regarding Humira’s intellectual property (IP) rights. As per the terms of the agreement, Boehringer Ingelheim received a non-exclusive license to Humira’s IP in the U.S.- scheduled to begin in July 2023.

 To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/tumor-necrosis-factor-tnf-inhibitor-drugs-market

Further key findings from the study suggest:

• Humira accounted for nearly half the revenue share of TNF inhibitor drugs market in 2018

• Emergence of biosimilars is anticipated to be the major growth rendering driver for the market

• Psoriasis is projected to be the most rapidly growing application segment over the forecast period

• Increased adoption of e-commerce is a key driver for online pharmacies

• TNF inhibitors faces an external threat from IL-inhibitors

Grand View Research has segmented the global tumor necrosis factor inhibitor drugs market on the basis of product, application, sales channel, and region:

TNF Inhibitor Drugs Product Outlook (Revenue, USD Million, 2014 - 2026)

• Humira

• Enbrel

• Remicade

• Simponi/Simponi Aria

• Cimzia

• Biosimilars

TNF Inhibitor Drugs Application Outlook (Revenue, USD Million, 2014 - 2026)

• Rheumatoid Arthritis

• Psoriasis

• Psoriatic Arthritis

• Crohn’s Disease

• Ulcerative Colitis

• Ankylosing Spondylitis

• Juvenile Idiopathic Arthritis

• Hidradenitis Suppurativa

• Others

TNF Inhibitor Drugs Sales Channel Outlook (Revenue, USD Million, 2014 - 2026)

• Hospital Pharmacies

• Specialty Pharmacies

• Online Pharmacies

TNF Inhibitor Drugs Regional Outlook (Revenue, USD Million, 2014 - 2026)

• North America

  • U.S.

  • Canada

• Europe

  • U.K.

  • Germany

  • Spain

  • France

  • Italy

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

• Latin America

  • Brazil

  • Mexico

  • Argentina

• MEA

  • South Africa

  • Saudi Arabia

  • UAE